Arcutis Biotherapeutics NASDAQ:ARQT President and CEO Todd Watanabe sold 40,000 shares of common stock on October 28, 2025, for approximately $1,001,032. The shares were sold at a weighted average price of $25.0258, in a range of $25.00 to $25.1691. The sale comes amid ARQT's impressive 192.96% price return over the past year and recent 24.3% surge in the past week.
Following the transaction, Watanabe directly owns 806,440 shares of Arcutis Biotherapeutics.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026.
Watanabe also indirectly owns shares through several trusts and an LLC: The John Franklin Watanabe Trust (25,410 shares), The Anderson Prest Watanabe Irrevocable Trust (25,410 shares), Watanabe Ventures, LLC (57,358 shares), and The Watanabe 2016 Irrevocable Trust (124,956 shares). He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.Despite not being profitable in the last twelve months, Arcutis boasts impressive 89.1% gross profit margins and a "GREAT" overall financial health score according to InvestingPro. Subscribers can access 14 additional ProTips and comprehensive Pro Research Reports that provide deeper insights into ARQT's valuation and growth prospects.
In other recent news, Arcutis Biotherapeutics Inc . reported a strong third-quarter performance, achieving profitability for the first time. The company posted earnings per share of $0.06, significantly surpassing the expected loss of $0.0886. Revenue also exceeded expectations, reaching $99.2 million, a 14.06% increase over projections. Following this performance, H.C. Wainwright raised its price target for Arcutis to $30, maintaining a Buy rating, while Mizuho increased its target to $32, citing strong execution and an Outperform rating. Both firms highlighted the company's successful earnings and revenue results as key factors in their revised outlooks. Arcutis management now anticipates reaching cash flow break-even in the fourth quarter of 2025, ahead of its previous target. These developments reflect the robust demand for its Zoryve product, contributing to the company's positive financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.